Roche set to conquer top market

Posted 20 June 2022 AM

All new listings considered at the PBAC's May intracycle meeting were recommended, including Roche's yet to be TGA approved eye drug Vabysmo, which is expected to hit blockbuster status.

The PBAC has recommended listing Vabysmo in two indications - neo-vascular (wet) age-related macular degeneration and diabetic macular oedema.

Its decision sets up a battle with the sponsors of current standard-of-care treatments, including Novartis' (Lucentis) and Bayer's (Eylea).

To see the whole article, please login